Watermark

Advancing Global Health

We believe that everyone should have access to innovative, life-changing medicines, regardless of their location. To achieve this, we are intentionally built in a responsible way – to broaden global access to innovative medicines through strategic cost and time advantages.

Scientist preparing a sample for cancer therapy treatment, a key step in treating cancer effectively.

Our Unique Approach

Our expansive internal resources and capabilities enhance our control over quality, speed, cost, and risk—key factors in delivering innovative, safe, and accessible therapies to patients worldwide. In 2024, our clinical operations team was able to execute ~95%1 of our clinical trials in-house.

1 This figure does not include healthy volunteer studies.

We are able to accelerate clinical trials due to our extensive geographic reach and our ability to share expertise and insights with markets across the globe. This approach allows us to save on costs and time by:

  • Recruiting patients in countries with large patient pools, which allows us to accelerate patient enrollment
  • Enrolling patients in a wide range of regions results in lower costs and diverse participation, which also supports the collection of robust data across all patient demographics
  • Strong site engagement and partnerships that enable early study concept review and quick site activation
  • Our fast-to-Proof of Concept (PoC) strategy that has been shown to deliver molecules to the clinic with industry leading speed.
  • BeOne medicines gained approval in 14 new countries in 2024
  • Over 24,000 patients have enrolled in clinical trials managed by BeOne to date

Upholding our value of Patients First, our Global Patient Safety team ensures the safe and effective use of our medicines from their first use in clinical trials to prescribed post-commercialization use.

For more information about our Science, please visit Medicines, Research & Development, and Pipeline.

Our Commitment to Access

Our vision is to transform the biotechnology industry, creating impactful medicines that will be accessible to more cancer patients around the world. Our global strategy to achieve this includes:

Commercial Reach

Expanding our commercial presence and distribution infrastructure in established and growing markets

Accessibility

Maintaining a flexible, collaborative approach to pricing and reimbursement

Support

Developing assistance programs, which include low- or no-cost medicines to eligible patients, where permissible

For more information, read about Our Approach to Affordability as well as our Expanded Access Programs and Patient Support Program.

Patient Engagement & Advocacy

We seek to ensure that our approach to drug development and commercialization accurately reflects patients’ true lived experiences and expectations—a central component of providing patients with meaningful treatment. Actively engaging with patients throughout clinical development ensures our therapies meet patient needs, which ultimately supports better outcomes.

Our strategies for global patient advocacy vary based on local healthcare systems, but in all regions we seek to identify and address barriers to treatment access. A crucial component of our success lies in ensuring the independence of patient organizations. These commitments are detailed in our Global Policy Position on Partnering with Patient Organizations.

For more information about our campaigns, please visit Cancer & Mental Health.